Guggenheim Securities has named ABIVAX Soci t Anonyme its top idea within biotechnology, reiterating a buy rating as the market waits for the company s ABTECT Part Two maintenance study readout. The investment bank s focus in its assessment is squarely on obefazimod s malignancy profile in the treatment of ulcerative colitis.
Guggenheim s review of pooled data from Phase IIa, Phase IIb and Phase III ulcerative colitis trials shows that obefazimod s observed rates for non-melanoma skin cancers (NMSCs) and non-NMSC malignancies per 100 patient-years sit toward the lower end of the company management s benchmark ranges. Those ranges are 0.7 to 1.4 events per 100 patient-years for NMSCs and 0.3 to 0.7 events per 100 patient-years for non-NMSCs.
Investor discussions cited by Guggenheim reveal an absence of clear consensus on what the proper event-rate threshold should be for either category, though most buy-side participants consider the company-provided ranges to be reasonable. The firm notes that if obefazimod s malignancy rates are reported in the readout toward the middle or lower portions of those bands, the market reaction should be constructive.
Classification and context driving investor reaction
Guggenheim points to two specific drivers that are influencing investor sentiment ahead of the readout. First, colonic dysplasia has been removed from obefazimod s malignancy classification so that the categorization aligns with conventions used by peer sponsors. Second, several malignancy signals observed in the data set notably prostate and breast cancer events are increasingly viewed by investors as unrelated to the drug.
The firm also emphasizes the need to interpret obefazimod s NMSC findings in the context of elevated background incidence for basal cell carcinoma and squamous cell carcinoma, rather than reading those events in isolation.
Market positioning and potential upside
Guggenheim describes the current setup into the ABTECT Part Two readout as conservative: some nervous investors have already trimmed positions, which could mute downside and set the stage for a more pronounced rebound if safety data are deemed clean and convincing. The firm projects that renewed investor demand, contingent on favorable safety outcomes, could push shares back into a $130 to $150 range.
On the efficacy front, ABIVAX recently reported topline Phase III ABTECT results indicating about a 40% placebo-adjusted clinical remission rate for obefazimod. That efficacy signal has generated mixed analyst responses: Jefferies moved to downgrade the stock to Hold, while Wedbush adjusted its view to Neutral.
Takeaway
Guggenheim s stance underscores that the upcoming maintenance study readout will be evaluated primarily through a safety lens, with malignancy rates and classification conventions shaping investor interpretation. Should obefazimod s numbers fall toward the lower end of the company s ranges and safety conclusions be persuasive, the firm expects that market demand could materially improve the stock s trading level.